Inside Textiles

Free membership

Receive our weekly Newsletter
and set tailored daily news alerts.


TissueGen appoints new Director of Quality Assurance

Seasoned biotech industry veteran to guide the company’s path towards clinical application and commercial scale-up of Elute fibre.

26th September 2017

Innovation in Textiles
 |  Dallas, TX


Edward G. Parent, Director, Quality Assurance. © TissueGenTissueGen, developer of Elute fibre, a biodegradable fibre format for advanced drug delivery, has announced that Edward Parent has been appointed Director, Quality Assurance to guide clinical application and commercial scale-up of its core technology.

Edward Parent brings over 35 years of experience working in a broad range of FDA regulated environments and guiding compliance with GMP requirements and various quality management systems.

Edward Parent

Parent’s diverse career has included positions with start-up companies like Biomatrix Inc. and Hylamed Inc / LuroMedLLC and large corporations such as Johnson & Johnson and Genzyme Biosurgery in roles including Director of Technical Operations, Principal Scientist, and Quality Engineer.

He has been responsible for advancing multiple early stage products from concept to clinical trial and commercialisation. Prior to joining TissueGen, Edward most recently served as a scientist atEvonik Industries, where he advised and implemented technology transfer, scale up, and new product development of biodegradable polymers.

“We see a tremendous opportunity for Elute fibre to redefine the way drug delivery, tissue engineering and nerve regeneration are approached. The combination of biotech, medical device and pharmaceutical industry expertise that Mr Parent brings to TissueGen will accelerate our path towards clinical application and scale up commercialization of Elute fibre-based products,” said Christopher Knowles, President and CEO of TissueGen.

Elute fibre

TissueGen’s Elute fibre can directly replace standard fibres in biodegradable medical textiles and may significantly improve clinical outcomes by delivering therapeutic agents directly at the surgical site, according to the manufacturer. Through localised delivery of drugs at the site of implantation, Elute fibres may orchestrate the body’s healing and regenerative processes.

“Elute fibre has the potential to play a pivotal role in the next-generation of medical devices and I am eager to apply the skills I’ve honed throughout my career to guide the company towards clinical application and large-scale commercialization,” said Parent.

Parent is a member of the Society for Biomaterials, Controlled Release Society and American Society for Quality. He is also a published author and holds four patents.

Latest Reports

Business intelligence for the fibre, textiles and apparel industries: technologies, innovations, markets, investments, trade policy, sourcing, strategy...

Find out more